Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

AIMS: To evaluate the efficacy and safety of imeglimin for up to 52 weeks as combination therapy with insulin in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: This double‐blind, randomized, parallel‐group phase 3 trial was performed at 35 sites in Japan. Eligible patients were indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Reilhac, Caroline, Dubourg, Julie, Thang, Carole, Grouin, Jean‐Marie, Fouqueray, Pascale, Watada, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302620/
https://www.ncbi.nlm.nih.gov/pubmed/34984815
http://dx.doi.org/10.1111/dom.14642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302620/
https://www.ncbi.nlm.nih.gov/pubmed/34984815
http://dx.doi.org/10.1111/dom.14642

Ejemplares similares